Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 3/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | PRCP | P42785 | 4/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | LHCGR | P22888 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 5/20 | 0.38 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664145 | 0.83 | GID4 (0.71) | GID4L3MBTL1PRCPKDM1ALHCGR | |
| SCHEMBL4339308 | 0.83 | GID4 (0.71) | GID4L3MBTL1PRCPKDM1ALHCGR | |
| SCHEMBL20912502 | 0.83 | GID4 (0.71) | GID4L3MBTL1PRCPKDM1ADRD3 | |
| SCHEMBL20912489 | 0.83 | GID4 (0.71) | GID4L3MBTL1PRCPKDM1ADRD3 | |
| SCHEMBL2359018 | 0.83 | GID4 (0.71) | GID4L3MBTL1PRCPKDM1ADRD3 | |
| SCHEMBL7880384 | 0.83 | GID4 (0.70) | GID4L3MBTL1PRCPKDM1AMAPT | |
| SCHEMBL7889930 | 0.83 | GID4 (0.70) | GID4L3MBTL1KDM1ALHCGR | |
| SCHEMBL4351835 | 0.81 | GID4 (0.70) | GID4L3MBTL1PRCPKDM1AHTR2A | |
| SCHEMBL4353119 | 0.80 | GID4 (0.67) | GID4L3MBTL1PRCPKDM1ALHCGR | |
| SCHEMBL7885697 | 0.80 | L3MBTL1 (1.00) | GID4L3MBTL1KDM1ALHCGRHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350093-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDROTHIENOPYRIDINES AS KCNQ2/3 MODULATORS FOR TREATING PAIN, EPILEPSY AND URINARY INCONTINENCE | GRUENENTHAL GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8268814-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| WO-2009124746-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275558-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | BDKRB2, BDKRB1, TRPV1 | GID4 2638/4885L3MBTL1 4835/4885PRCP 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.